Merck & Co., Inc., P.O. Box 2000, 126 East Lincoln Avenue, Rahway, NJ, 07065, USA.
ConcertAI, LLC, 1120 Massachusetts Ave., Cambridge, MA, 02138, USA.
BMC Pulm Med. 2024 Jul 10;24(1):332. doi: 10.1186/s12890-024-03138-y.
Real-world data regarding patient characteristics, adjuvant treatment patterns, and long-term survival outcomes are needed to better understand unmet needs among patients with completely resected early-stage non-small cell lung cancer (NSCLC).
Electronic medical records from the U.S.-based ConcertAI Patient360™ database were analyzed in patients with stage IB-IIIA NSCLC who underwent complete resection prior to March 1, 2016. Patients were followed until death or July 1, 2021. This study evaluated adjuvant chemotherapy use, and overall survival (OS) and real-world disease-free survival (rwDFS) outcomes using the Kaplan-Meier method. The correlation between OS and rwDFS was assessed using the Kendall rank test. Among patients who did not recur 5 years following surgery, landmark analyses of OS and rwDFS were conducted to understand the subsequent survival impact of remaining disease-free for at least 5 years.
Data from 441 patients with completely resected stage IB-IIIA NSCLC were included. About 35% of patients received adjuvant chemotherapy post-resection. Median OS and rwDFS from resection were 83.1 months and 42.4 months, respectively. The 5-year OS and rwDFS rates were 65.7% and 42.1%, respectively. OS and rwDFS were positively correlated (Kendall rank correlation coefficient = 0.67; p < 0.0001). Among patients without recurrence within 5 years after resection, the subsequent 5-year OS and rwDFS survival rates were 52.9% and 36.6%, respectively.
Use of adjuvant chemotherapy was low, and the overall 5-year OS rate remained low despite all patients having undergone complete resection. Patients who remained non-recurrent over time had favorable subsequent long-term survival.
需要真实世界的数据来更好地了解完全切除的早期非小细胞肺癌（NSCLC）患者的患者特征、辅助治疗模式和长期生存结果，以满足未满足的需求。
分析美国 ConcertAI Patient360™数据库中于 2016 年 3 月 1 日前接受完全切除术的 IB-IIIA 期 NSCLC 患者的电子病历。患者随访至死亡或 2021 年 7 月 1 日。本研究评估了辅助化疗的使用情况，以及使用 Kaplan-Meier 法评估总生存（OS）和真实世界无病生存（rwDFS）结果。使用 Kendall 秩检验评估 OS 与 rwDFS 之间的相关性。对于手术后 5 年内未复发的患者，进行 OS 和 rwDFS 的里程碑分析，以了解至少 5 年无疾病生存对随后生存的影响。
纳入 441 例完全切除的 IB-IIIA 期 NSCLC 患者的数据。约 35%的患者术后接受辅助化疗。从切除开始的中位 OS 和 rwDFS 分别为 83.1 个月和 42.4 个月。5 年 OS 和 rwDFS 率分别为 65.7%和 42.1%。OS 和 rwDFS 呈正相关（Kendall 秩相关系数=0.67；p<0.0001）。在切除后 5 年内无复发的患者中，随后 5 年的 OS 和 rwDFS 生存率分别为 52.9%和 36.6%。
尽管所有患者均接受了完全切除术，但辅助化疗的使用率较低，整体 5 年 OS 率仍然较低。随着时间的推移，无复发的患者有良好的后续长期生存。
